MBCProject_0040_T2_RNA
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.540
- XENOBIOTIC_METABOLISM+0.510
- MYC_TARGETS_V1+0.460
- G2M_CHECKPOINT+0.450
- OXIDATIVE_PHOSPHORYLATION+0.450
- BILE_ACID_METABOLISM+0.440
- FATTY_ACID_METABOLISM+0.430
- MYC_TARGETS_V2+0.400
- MTORC1_SIGNALING+0.320
- COAGULATION+0.300
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.470
- TGF_BETA_SIGNALING-0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
- TNFA_SIGNALING_VIA_NFKB-0.450
- APICAL_JUNCTION-0.420
- HEDGEHOG_SIGNALING-0.390
- IL6_JAK_STAT3_SIGNALING-0.390
- INFLAMMATORY_RESPONSE-0.370
- ALLOGRAFT_REJECTION-0.360
- UV_RESPONSE_DN-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR975587 | — | — | 0.867 |
| 2 | SRR1313126 | — | C | 0.866 |
| 3 | SRR1313127 | — | B | 0.862 |
| 4 | SRR8518448 | — | C | 0.858 |
| 5 | TCGA-P3-A5QF-01A-11R-A28V-07 | — | — | 0.851 |
| 6 | AUR-AFUM-TTM1-A-1-1-R-A743-41 | — | E | 0.848 |
| 7 | SRR2932846 | — | — | 0.847 |
| 8 | fddf611e-f586-49e1-9ee8-8ac853accb9e | — | — | 0.845 |
| 9 | SRR1516095 | — | — | 0.838 |
| 10 | TCGA-37-5819-01A-01R-1635-07 | — | cohortA3 | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.450 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.440 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.430 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.280 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.230 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |